Barclays Starts Amneal Pharmaceuticals (AMRX) at Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AMRX Hot Sheet
Price: $19.10 -5.49%
Rating Summary:
8 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
8 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Barclays analyst Balaji Prasad initiates coverage on Amneal Pharmaceuticals (NYSE: AMRX) with a Equalweight rating and a price target of $9.00.
For an analyst ratings summary and ratings history on Amneal Pharmaceuticals click here. For more ratings news on Amneal Pharmaceuticals click here.
Shares of Amneal Pharmaceuticals closed at $7.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amneal Pharmaceuticals (AMRX) PT Raised to $25 at JPMorgan
- Barclays Starts Technoprobe SpA (TPRO:IM) at Overweight
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
